dose limiting toxicity dose level has not been identified in doses up to 250 mg/day Preclinical posters strengthen the NXP900 clinical development strategy as single agent in biomarker-targeted ...

The annual event for the military medical research and development community had another successful year as a record 800 ...

While advancements in VR technology have improved user engagement, existing systems often inadequately integrate vibrotactile and kinesthetic feedback with auditory and visual elements, limiting the ...

Title: ZW1528, a Bispecific Antibody Targeting IL-4Ra and IL-33, Potently Inhibits Key Mediators of Airway Inflammation ...

Dr. David Bingaman, Chief Development Officer ... of clinical and preclinical trial endpoint and technology services, will be presenting a poster at the Association for Research in Vision and ...

a provider of preclinical development services. Utilizing its proprietary CAB platform technology, BioAtla develops novel, reversibly active monoclonal and bispecific antibodies and other protein ...

Multiple Poster Presentations Highlight the Depth and Novelty of MeiraGTx’s Technology Platforms for Gene and Cell TherapyLONDON and NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc ...

Sutro Biopharma, Inc. announced its participation in the 2025 American Association for Cancer Research Annual Meeting, presenting key data on its novel exatecan Tissue Factor antibody drug ...

Explore the simulation, edutainment, or visualization landscape as you enhance your game design and development skills to create truly innovative games. In the game design master’s degree, you will ...

The poster is scheduled for presentation on May 31 ... is a first-in-class investigational telomere-targeting agent currently in clinical development to evaluate its activity in non-small cell lung ...